Invacare stock blooms in April, gaining 4-1/4 points to lead O-T-C Index.
This article was originally published in The Gray Sheet
Executive SummaryINVACARE STOCK STORMS AHEAD 4-1/4 POINTS TO 39-1/2 IN APRIL, advancing for the third consecutive month. The issue, the largest point gainer in April among the 40 O-T-C issues tracked by "The Gray Sheet," realized most of its 12.1% increase following the company's April 20 release of strong first quarter sales and earnings figures.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.